In an uncontrolled phase I dose-ranging study with MM patients [15], an increase in maximum drug concentration (Cmax) and the area under the concentration–time curve (AUC) of lenalidomide (25 mg/day) was observed with increasing doses of temsirolimus (15–20 mg/day), a known P-gp inhibitor/substrate. Here, PGP is linked to Miyoshi myopathy.